Role of Biosimilars in the Oncology Ecosystem

Before the Hatch-Waxman Act of 1984, only 35% of brand name drugs had to contend with generic competition, presently nearly all eligible drugs are faced with generic competition. As the number of generic drugs competing with a brand drug increases, the relative price per dose decreases. The 2009 introduction of the Biologics Price Competition and Innovation Act is intended to abbreviate the biosimilar pathway and expedite lower-cost alternatives to biologics. While biosimilars and generics are not the same, biosimilars are very likely to adopt the same role in the market over the next decade; however, their safety, efficacy, and general role in the clinical setting remains unclear.  

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe the role of biosimilars in the oncology ecosystem and cost reductions resulting from their use. 
  • Identify the challenges of implementing biosimilars in a clinical setting, including concerns about safety and efficacy.
     
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • BeiGene, Ltd.
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Eisai
  • Genentech, a member of the Roche Group
  • Ipsen Biopharmaceuticals, Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • NOVOCURE
  • Pfizer Inc.
  • Puma Biotechnology
  • Sanofi Genzyme
  • Taiho Oncology, Inc.
  • TESARO, a GSK Company

 This activity is supported by independent medical education grants from:

  • Bristol-Myers Squibb
  • Illumina, Inc.

This activity is supported by independent educational grants from:

  • AbbVie
  • Astellas
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Incyte
  • Merck & Co., Inc.

This activity is supported by a medical education grant from Exelixis, Inc.

This activity is supported by an unrestricted educational grant from Kite, a Gilead Company

This project has been made possible in part by a grant from the Varian Medical Systems Educational Grant Corporate Fund, an advised fund of Silicon Valley Community Foundation

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
05/15/2020
Course expires: 
03/01/2021
Cost:
$0.00
Part of: 
NCCN 2020 Virtual Annual Conference

Moderator: 
Michael I. Rabin, MBA, MPA    
City of Hope National Medical Center    

Panelists: 
Michael Kolodziej, MD    
ADVI Health, Inc.     

Drew S. Mace, PharmD    
Ann B. Barshinger Cancer Institute    

Bhuvana Sagar, MD    
Cigna Health Care    

Scott A. Soefje, PharmD, MBA, BCOP    
Mayo Clinic Cancer Center
 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:
Drew S. Mace, PharmD 
Michael I. Rabin, MBA, MPA

The faculty listed below discloses the following relevant financial relationships:
Michael Kolodziej, MD
Aetna: Equity Interest/Stock Options
CVS Health: Equity Interest/Stock Options

Bhuvana Sagar, MD
Cigna Health Care: Equity Interest/Stock Options; Salary

Scott A. Soefje, PharmD, MBA, BCOP
Pfizer Inc.: Product/Speakers Bureau
Spectrum Pharmaceuticals, Inc.: Consulting Fee

NCCN Staff Disclosures 

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; C. Lyn Fitzgerald (employed by NCCN until 3/31/20); Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Diana Krause, MHA; James McCanney, JD; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Jessica Sugalski, MPPA; Sarah Weinstein; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Wui-Jin Koh, MD
IBM Watson Health for Oncology and Genomics; Scientific Advisor

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-20-065-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits.  Approval is valid until March 1, 2021. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: